|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The most important are associations between rs966423 and mortality (HR = 1.60, p = 0.038), extrathyroidal extension (ETE) (OR = 1.57, p = 0.019); rs965513 and tumour diameter (slope of regression 0.14, p = 0.025), lymph node metastasis (OR = 1.59, p = 0.030) and ETE (OR = 1.29, p = 0.045); rs944289 and distant metastasis (OR = 0.58, p = 0.042); and rs116909374 and lymph node metastasis (OR = 0.61, p = 0.016).
|
31681970 |
2019 |
|
Neoplasm Metastasis
|
|
0.030 |
GeneticVariation
|
BEFREE |
The most important are associations between rs966423 and mortality (HR = 1.60, p = 0.038), extrathyroidal extension (ETE) (OR = 1.57, p = 0.019); rs965513 and tumour diameter (slope of regression 0.14, p = 0.025), lymph node metastasis (OR = 1.59, p = 0.030) and ETE (OR = 1.29, p = 0.045); rs944289 and distant metastasis (OR = 0.58, p = 0.042); and rs116909374 and lymph node metastasis (OR = 0.61, p = 0.016).
|
31681970 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
|
0.020 |
GeneticVariation
|
BEFREE |
The most important are associations between rs966423 and mortality (HR = 1.60, p = 0.038), extrathyroidal extension (ETE) (OR = 1.57, p = 0.019); rs965513 and tumour diameter (slope of regression 0.14, p = 0.025), lymph node metastasis (OR = 1.59, p = 0.030) and ETE (OR = 1.29, p = 0.045); rs944289 and distant metastasis (OR = 0.58, p = 0.042); and rs116909374 and lymph node metastasis (OR = 0.61, p = 0.016).
|
31681970 |
2019 |
|
Differentiated Thyroid Gland Carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
This meta-analysis revealed that common variations of FOXE1 (rs965513, rs944289 and rs1867277) were risk factors associated with increased DTC susceptibility.
|
29788924 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The functional variants rs965513 and rs1867277 independently contribute to genetic predisposition to PTC, while a contributing role of the FOXE1 poly-Ala polymorphism could not be confirmed.
|
27824288 |
2017 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
There were significant associations of all SNPs with PTC (rs965513 odds ratio [OR] = 1.72, p = 8 × 10-7; rs1867277 OR = 1.59, p = 1 × 10-6; rs1443434 OR = 1.53, p = 1 × 10-5; rs944289 OR = 1.52, p = 4 × 10-5).
|
28660995 |
2017 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We propose that the interaction between the lncRNA, its binding protein MYH9, and the coding gene FOXE1 underlies the predisposition to PTC triggered by rs965513.
|
28049826 |
2017 |
|
Thyroid carcinoma
|
|
0.860 |
GeneticVariation
|
BEFREE |
The A allele of rs965513 polymorphism was shown to be highly associated with risk of thyr</span>oid cancer, with odds ratios of 1.58 (95% CI 1.32-1.90) in all populations, 1.65 (95% CI 1.31-2.07)) in Caucasian populations and 1.49 in Asian populations.
|
27191655 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the association between rs965513 and PTC in different ethnicities and countries, we conducted a meta-analysis using relatively large-scale samples from 23 studies (N = 163,136; 20,736 cases and 142,400 controls) by searching the PubMed and Google Scholar databases.
|
27191655 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Five germline genetic variants (rs116909374, rs965513, rs944289, rs966423, and rs2439302) have been associated in genome-wide association studies (GWAS) with increased risk of differentiated thyroid cancer (DTC), but their role in mortality of patients has not been established.
|
26490305 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Among Europeans, we found that the two SNPs previously reported at 9q22 were not independently associated to DTC and that rs965513 was the predominant signal; at 14q13, we showed that the haplotype rs944289[C]-rs116909374[C]-rs999460[T] was significantly associated with DTC risk and that the association with rs116909374 differed by smoking status (p-interaction = 0.03).
|
26991144 |
2016 |
|
Differentiated Thyroid Gland Carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Furthermore, DTC risk was positively associated with the number of copies in the minor allele (A) of rs965513 among people who consumed less iodine than the median.
|
27610545 |
2016 |
|
Malignant neoplasm of thyroid
|
|
0.060 |
GeneticVariation
|
BEFREE |
The A allele of rs965513 polymorphism was shown to be highly associated with risk of thyr</span>oid cancer, with odds ratios of 1.58 (95% CI 1.32-1.90) in all populations, 1.65 (95% CI 1.31-2.07)) in Caucasian populations and 1.49 in Asian populations.
|
27191655 |
2016 |
|
Thyroid Neoplasm
|
|
0.060 |
GeneticVariation
|
BEFREE |
The A allele of rs965513 polymorphism was shown to be highly associated with risk of thyr</span>oid cancer, with odds ratios of 1.58 (95% CI 1.32-1.90) in all populations, 1.65 (95% CI 1.31-2.07)) in Caucasian populations and 1.49 in Asian populations.
|
27191655 |
2016 |
|
Primary differentiated carcinoma of thyroid gland
|
|
0.050 |
GeneticVariation
|
BEFREE |
Furthermore, DTC risk was positively associated with the number of copies in the minor allele (A) of rs965513 among people who consumed less iodine than the median.
|
27610545 |
2016 |
|
Primary differentiated carcinoma of thyroid gland
|
|
0.050 |
GeneticVariation
|
BEFREE |
Among Europeans, we found that the two SNPs previously reported at 9q22 were not independently associated to DTC and that rs965513 was the predominant signal; at 14q13, we showed that the haplotype rs944289[C]-rs116909374[C]-rs999460[T] was significantly associated with DTC risk and that the association with rs116909374 differed by smoking status (p-interaction = 0.03).
|
26991144 |
2016 |
|
Primary differentiated carcinoma of thyroid gland
|
|
0.050 |
GeneticVariation
|
BEFREE |
Five germline genetic variants (rs116909374, rs965513, rs944289, rs966423, and rs2439302) have been associated in genome-wide association studies (GWAS) with increased risk of differentiated thyroid cancer (DTC), but their role in mortality of patients has not been established.
|
26490305 |
2016 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The risk allele of rs965513 was associated with larger tumor size (p = 0.025) and extrathyroidal expansion (odd ratio [OR] = 1.29, p = 0.045).
|
27342578 |
2016 |
|
Thyroid carcinoma
|
|
0.860 |
GeneticVariation
|
GWASCAT |
Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations.
|
25855579 |
2015 |
|
Thyroid carcinoma
|
|
0.860 |
GeneticVariation
|
BEFREE |
These results explain the mechanism by which the risk allele of rs965513 predisposes to thyroid cancer.
|
25918370 |
2015 |
|
Thyroid carcinoma
|
|
0.860 |
GeneticVariation
|
BEFREE |
For rs965513, individuals carrying the risk A allele, compared to individuals with the G allele, had 31 % higher risk of thyroid cancer (A vs. G: OR 1.31, 95 % CI 1.17-1.46).
|
26206751 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We genotyped rs965513 from PTC patients and measured gene expression levels by real-time RT-PCR in unaffected thyroid tissue and matched tumor.
|
25303483 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Four GWAS-identified SNPs of papillary thyroid cancer (PTC), rs965513, rs944289, rs966423 and rs2439302, were genotyped in a case-control study of 838 patients with PTC and 501 patients with benign thyroid tumor (BTT) from the Chinese Han population.
|
25746573 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The [A] allele of SNP rs965513 in 9q22 has been consistently shown to be highly associated with increased papillary thyroid cancer (PTC</span>) risk with an odds ratio of ∼1.8 as determined by genome-wide association studies, yet the molecular mechanisms remain poorly understood.
|
25918370 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Similarly, the rs965513 on the TTF2 can also elevate the risk of PTC significantly (GA vs GG, OR = 1.67, 95% CI = 1.07-2.59; AA+GA vs AA, OR = 1.37, 95% CI = 1.09-1.82; A vs G, OR = 1.29, 95% CI = 1.05-1.59).
|
26356687 |
2015 |